GlobeNewsWire
06 Oct 2026, 19:51 UTC · 55m ago
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
Impact · against what's priced in
Aardvark Therapeutics faces a new class action lawsuit alleging material misstatements regarding its business operations and the safety of its lead candidate, ARD-101. The legal action introduces potential settlement liabilities and creates a drag on future earnings, negatively impacting the company's risk profile.
- AARD−0.50
No priced-in read yet





